JP6826463B2 - Component analyzer - Google Patents

Description

The present invention relates to a component analyzer and is suitable for analyzing components in blood.

Regarding component analysis in blood, for example, the eyeball's corneum is irradiated with a monochromatic or single-wavelength excitation light beam in the visible to near-infrared region, and based on the Raman scattering spectrum obtained from the corneum. An analyzer that analyzes intraocular blood glucose has been proposed (see Patent Document 1 below).

According to Patent Document 1, the excitation 420～1500Cm ^-1 or 2850～3000Cm ^-1 in a shift wavenumber from the wavelength, preferably ^{420~450cm -1, 460~550cm -1, 750~800cm -1} , 850~ ^{940cm -1, 1000~1090cm -1, 1090~1170cm -1} , 1200~1300cm -1, 1300~1390cm -1, glucose quantitated using a Raman scattering peak at 1400～1500Cm ^-1 or 2850～3000Cm ^-1 It is stated that it is possible.

The excitation 550～1500Cm ^-1 or 2900～3050Cm ^-1 in a shift wavenumber from the wavelength, preferably ^{550~620cm -1, 650~700cm -1, 780~870cm -1} , 900~980cm -1, 1000~ It is stated that fructose, a sugar other than glucose, can be quantified using Raman scattering peaks at 1150 cm ^-1 , 1200 to 1300 cm ^-1 , 1400 to 1480 cm ^-1 or 2900 to 3050 cm ^-1 .

Japanese Unexamined Patent Publication No. 9-12207

However, in the analyzer of Patent Document 1, there is a portion where the numerical values overlap between the Raman scattering peak used for quantifying glucose and the Raman scattering peak used for quantifying fructose. Therefore, in the analyzer of Patent Document 1, it is doubtful whether the quantified blood component indicates a component to be truly quantified, and it is considered that the reliability of the analysis result is lacking.

Therefore, the present invention proposes a component analyzer that can improve the reliability of analysis results.

The component analyzer of the present invention is contained in blood or interstitial fluid based on a spectrum acquisition unit that acquires a Raman spectrum showing an intensity distribution for each wavelength in Raman scattered light and a Raman spectrum acquired by the spectrum acquisition unit. It is characterized by including a component identification unit for searching for and identifying a plurality of types of sugar components.

With such a component analyzer, it is possible to subdivide and quantify the sugar component contained in blood or interstitial fluid, which is one of the important indicators in the detection and treatment of diseases such as diabetes, and there are a plurality of types. It is possible to give more detailed information than when the sugar component of diabetes is grasped from a broad perspective.

It is preferable that the component identification unit searches for and identifies the sugar components of monosaccharides, disaccharides, and trisaccharides.

In this case, it is possible to subdivide the structurally similar types of saccharides and quantify them more locally, and it is possible to give detailed information accordingly.

Further, it is preferable that the component identification unit searches for a plurality of types of sugar components contained in the blood or the interstitial fluid and also searches for and identifies the urea component contained in the blood or the interstitial fluid.

In this way, it is possible to provide an important index for the prevention, early detection and treatment of diabetes, as well as the prevention, early detection and treatment of renal diseases that are likely to be associated with diabetes.

Further, it is preferable that the component identification unit searches for a plurality of types of sugar components contained in the blood or the interstitial fluid and also searches for and identifies a drug component contained in the blood or the interstitial fluid.

In this way, it becomes possible to quantify the drug component having a possibility of affecting the sugar component in blood or interstitial fluid together with the sugar component. Therefore, when the sugar component contained in blood or interstitial fluid is not within the normal range, it is possible to provide an index for determining whether or not the factor is a drug component.

Further, it is preferable that the component identification unit searches for a plurality of types of sugar components contained in the blood or the interstitial fluid and also searches for and identifies the ascorbic acid component contained in the blood or the interstitial fluid.

In this way, the presence or absence of ascorbic acid deficiency due to diabetes can be given as information. Therefore, important indicators for the prevention, early detection and treatment of diabetes can be given in more detail.

Further, when a peak corresponding to a component contained in the blood or the interstitial fluid is detected from the Raman spectrum acquired by the spectrum acquisition unit, a quantification unit for determining the concentration based on the intensity of the peak is further provided. It may be a thing.

Further, it is preferable to further provide a notification unit for notifying that the drug component is present in the blood or the interstitial fluid when the concentration of the drug component contained in the blood or the interstitial fluid is equal to or higher than a specified value.

In this way, when the concentration of the sugar component contained in blood or interstitial fluid is not within the normal range, it is possible to give an opportunity to determine whether or not the factor is a drug component.

Further, the component analyzer of the present invention has a spectrum acquisition unit that acquires a Raman spectrum showing an intensity distribution for each wavelength in Raman scattered light, and a peak that appears in the Raman spectrum depending on the components contained in blood or interstitial fluid. The blood is provided with a component identification unit that searches for and identifies a component contained in the blood or the interstitial fluid based on the wave number set as the central wave number and the Raman spectrum acquired by the spectrum acquisition unit. Alternatively, 904 cm ^-1 is set as the central wave number of the peak appearing in the Raman spectrum when the interstitial liquid contains a glucose component.

Experiments have confirmed that when the glucose component is contained in blood or interstitial fluid, a peak appears accurately at 904 cm ^-1 of the Raman spectrum and its reproducibility is also present. Therefore, it is possible to pinpoint the glucose component in blood or interstitial fluid and accurately quantify it.

Further, the component analyzer of the present invention has a spectrum acquisition unit that acquires a Raman spectrum showing an intensity distribution for each wavelength in Raman scattered light, and a peak that appears in the Raman spectrum depending on the components contained in blood or interstitial fluid. The blood is provided with a component identification unit that searches for and identifies a component contained in the blood or the interstitial fluid based on the wave number set as the central wave number and the Raman spectrum acquired by the spectrum acquisition unit. or around wavenumber of the peak appearing in the Raman spectrum when it contains fructose component to the interstitial fluid, characterized in that the 620 cm ^-1 and 2940 cm ^-1 are set.

If the fructose component is contained in the blood or interstitial fluid, the exact peak at 620 cm ^-1 and 2940 cm ^-1 of the Raman spectrum is also its reproducibility occurrence has been confirmed by experiments. Therefore, it is possible to pinpoint the fructose component in blood or interstitial fluid and accurately quantify it.

Further, the component analyzer of the present invention has a spectrum acquisition unit that acquires a Raman spectrum showing an intensity distribution for each wavelength in Raman scattered light, and a peak that appears in the Raman spectrum depending on the components contained in blood or interstitial fluid. The blood is provided with a component identification unit that searches for and identifies a component contained in the blood or the interstitial fluid based on the wave number set as the central wave number and the Raman spectrum acquired by the spectrum acquisition unit. Alternatively, when the interstitial liquid contains a Martose component, the central wavenumbers of the peaks appearing in the Raman spectrum are set to 546 cm ^-1 and 2898 cm ^-1 .

If the maltose component is contained in the blood or interstitial fluid, the exact peak at 546cm ^-1 and 2898cm ^-1 of Raman spectrum is also its reproducibility occurrence has been confirmed by experiments. Therefore, it is possible to pinpoint the maltose component in blood or interstitial fluid and accurately quantify it.

Further, the component analyzer of the present invention has a spectrum acquisition unit that acquires a Raman spectrum showing an intensity distribution for each wavelength in Raman scattered light, and a peak that appears in the Raman spectrum depending on the components contained in blood or interstitial fluid. The blood is provided with a component identification unit that searches for and identifies a component contained in the blood or the interstitial fluid based on the wave number set as the central wave number and the Raman spectrum acquired by the spectrum acquisition unit. Alternatively, when the interstitial liquid contains a maltotriose component, the central wavenumbers of the peaks appearing in the Raman spectrum are set to 470 cm ^-1 and 922 cm ^-1 .

If maltotriose component is contained in the blood or interstitial fluid, the exact peak at 470 cm ^-1 and 922cm ^-1 in a Raman spectrum is also its reproducibility occurrence has been confirmed by experiments. Therefore, it is possible to pinpoint the maltotriose component in blood or interstitial fluid and accurately quantify it.

Further, the component analyzer of the present invention has a spectrum acquisition unit that acquires a Raman spectrum showing an intensity distribution for each wavelength in Raman scattered light, and a peak that appears in the Raman spectrum depending on the components contained in blood or interstitial fluid. The blood is provided with a component identification unit that searches for and identifies a component contained in the blood or the interstitial fluid based on the wave number set as the central wave number and the Raman spectrum acquired by the spectrum acquisition unit. Alternatively, when the interstitial liquid contains a urea component, 1002 cm ^-1 is set as the central wave number of the peak appearing in the Raman spectrum.

Experiments have confirmed that when the urea component is contained in blood or interstitial fluid, it appears accurately at 1002 cm ^-1 in the Raman spectrum and has its reproducibility. Therefore, it is possible to pinpoint the urea component in blood or interstitial fluid and accurately quantify it.

Further, the component analyzer of the present invention has a spectrum acquisition unit that acquires a Raman spectrum showing an intensity distribution for each wavelength in Raman scattered light, and a peak that appears in the Raman spectrum depending on the components contained in blood or interstitial fluid. The blood is provided with a component identification unit that searches for and identifies a component contained in the blood or the interstitial fluid based on the wave number set as the central wave number and the Raman spectrum acquired by the spectrum acquisition unit. features or around wavenumber of the peak appearing in the Raman spectrum when it contains acetylsalicylic acid component to the interstitial ^{fluid, 804cm -1, 1032cm -1,} that 1152Cm ^-1 and 1198cm ^-1 are set And.

When the acetylsalicylic acid component is contained in blood or interstitial fluid, it appears accurately in Raman spectra of 804 cm ^-1 , 1032 cm ^-1 , 1152 cm ^-1 and 1198 cm ^-1 , and its reproducibility is confirmed by experiments. Has been done. Therefore, it is possible to pinpoint the acetylsalicylic acid component in blood or interstitial fluid and accurately quantify it.

Further, the component analyzer of the present invention has a spectrum acquisition unit that acquires a Raman spectrum showing an intensity distribution for each wavelength in Raman scattered light, and a peak that appears in the Raman spectrum depending on the components contained in blood or interstitial fluid. The blood is provided with a component identification unit that searches for and identifies a component contained in the blood or the interstitial fluid based on the wave number set as the central wave number and the Raman spectrum acquired by the spectrum acquisition unit. Alternatively, when the stromal liquid contains an acetaminophen component, the central wavenumbers of the peaks appearing in the Raman spectrum are set to 854 cm ^-1 and 1324 cm ^-1 .

If acetaminophen component is contained in the blood or interstitial fluid, it appeared exactly at 854cm ^-1 and 1324cm ^-1 of Raman spectrum there is also the reproducibility has been confirmed by experiments. Therefore, it is possible to pinpoint the acetaminophen component in blood or interstitial fluid and accurately quantify it.

Further, the component analyzer of the present invention has a spectrum acquisition unit that acquires a Raman spectrum showing an intensity distribution for each wavelength in Raman scattered light, and a peak that appears in the Raman spectrum depending on the components contained in blood or interstitial fluid. The blood is provided with a component identification unit that searches for and identifies a component contained in the blood or the interstitial fluid based on the wave number set as the central wave number and the Raman spectrum acquired by the spectrum acquisition unit. Alternatively, when the stromal liquid contains ascorbic acid, the central wavenumbers of the peaks appearing in the Raman spectrum are set to 820 cm ^-1 and 1682 cm ^-1 .

If ascorbic acid component is contained in the blood or interstitial fluid, it appeared exactly at 820 cm ^-1 and 1682 cm ^-1 in the Raman spectrum there is also the reproducibility has been confirmed by experiments. Therefore, it is possible to pinpoint the ascorbic acid component in blood or interstitial fluid and accurately quantify it.

As described above, according to the present invention, there is provided a component analyzer capable of improving the reliability of analysis results.

It is a figure which shows the structure of the component analysis system. It is a figure which shows the structure of the component analyzer in 1st Embodiment. It is a graph which illustrates the calibration curve of glucose. It is a graph which illustrates the calibration curve of fructose. It is a graph which illustrates the calibration curve of maltose. It is a graph which illustrates the calibration curve of maltotriose. It is a flowchart which shows the 1st component analysis method. It is a figure which shows the structure of the component analyzer in 2nd Embodiment. It is a flowchart which shows the 2nd component analysis method. It is a figure which shows the structure of another component analysis system. It is a figure which shows the Raman spectrum of the aqueous solution sample containing the glucose component of a known concentration. It is a figure which shows the Raman spectrum (200cm ^-1 ~ 1000cm ^-1 ) of the aqueous solution sample containing a fructose component of a known concentration. It is a figure which shows the Raman spectrum (2700cm ^-1 ~ 3100cm ^-1 ) of the aqueous solution sample containing a fructose component of a known concentration. It is a figure which shows the Raman spectrum (200cm ^-1 ~ 1000cm ^-1 ) of the aqueous solution sample containing the maltose component of a known concentration. It is a figure which shows the Raman spectrum (2700cm ^-1 ~ 3100cm ^-1 ) of the aqueous solution sample containing the maltose component of a known concentration. It is a figure which shows the Raman spectrum (200cm ^{-1 to} 1000cm ^-1 ) of the aqueous solution sample containing the maltotriose component of a known concentration. It is a figure which shows the Raman spectrum (800cm ^{-1 to} 1000cm ^-1 ) of the aqueous solution sample containing the maltotriose component of a known concentration. It is a figure which shows the Raman spectrum of the aqueous solution sample containing the urea component of a known concentration. It is a figure which shows the Raman spectrum (200cm- ^{1 to} 1000cm- ¹ ) of the aqueous solution sample containing the acetylsalicylic acid component of a known concentration. It is a diagram showing a Raman spectrum of an aqueous solution sample containing acetylsalicylic acid component of known concentration ^{(1000cm -1 ~1500cm} -1). It is a figure which shows the Raman spectrum (200cm ^-1 ~ 1000cm ^-1 ) of the aqueous solution sample containing acetaminophen component of a known concentration. It is a diagram showing a Raman spectrum of the aqueous solution samples containing acetaminophen component of known concentration ^{(1000cm -1 ~3000cm} -1). It is a figure which shows the Raman spectrum (800cm ^-1 ~ 1000cm ^-1 ) of the aqueous solution sample containing the ascorbic acid component of a known concentration. It is a diagram showing a Raman spectrum of an aqueous solution sample containing ascorbic acid component of known concentration ^{(1000cm -1 ~3000cm} -1).

Hereinafter, embodiments and modifications thereof for carrying out the component analyzer according to the present invention will be illustrated together with the accompanying drawings. The embodiments illustrated below and examples thereof are intended to facilitate understanding of the present invention, and are not intended to limit the interpretation of the present invention. The present invention can be modified and improved without departing from the spirit of the present invention.

(1) Embodiment <Structure of component analysis system>
FIG. 1 is a diagram showing a configuration of a component analysis system. As shown in FIG. 1, the component analysis system 1 of the first embodiment is a system that disperses and analyzes the Raman scattered light generated in the sample SPL by irradiation with excitation light, and analyzes the light source 2, the reflector 3, and the optical system. 4. The spectroscope 5 and the component analyzer 6 are provided as main components. In the present embodiment, blood collected from a person is used as a sample SPL.

The light source 2 emits excitation light to irradiate the sample SPL. The shorter the excitation wavelength of the excitation light, the higher the Raman scattering efficiency and the higher the spatial resolution. Therefore, a solid-state laser is preferable as the light source 2. Since the spectrum of Raman scattered light shows the difference in the wave number of Raman scattered light (Raman shift amount) with respect to the wave number of the excitation light, it is preferable that the excitation wavelength is a single wavelength. As a specific example of this excitation wavelength, for example, a single wavelength selected from 514 nm, 532 nm, 633 nm, 670 nm, and 785 nm is used.

The reflector 3 reflects the light emitted from the light source 2 and guides it to the sample SPL. As long as the light emitted from the light source 2 is guided to the sample SPL, another member may be adopted instead of the reflector 3 or in addition to the reflector 3.

The optical system 4 guides the Raman scattered light generated in the sample SPL to the spectroscope 5. When the sample SPL is irradiated with excitation light, the interaction between the excitation light and the sample SPL causes Raman scattered light having a wavelength different from the wavelength of the excitation light in the sample SPL, and Rayleigh having the same wavelength as the excitation light. Scattered light is generated. The optical system 4 of the present embodiment has a filter 41 for removing the Rayleigh scattered light on the waveguide, and guides the Raman scattered light obtained through the filter 41 to the spectroscope 5. ..

The spectroscope 5 has a diffraction grid 51 and a photodetector 52. The diffraction grid 51 divides the light supplied from the sample SPL via the optical system 4 for each wavelength and guides the light to the light receiving surface of the photodetector 52. The photodetector 52 has a plurality of light receiving elements arranged one-dimensionally or two-dimensionally in the light receiving surface. The light detector 52 stores charges proportional to the intensity of Raman scattered light of each wavelength exposed to the light receiving element in the light receiving surface, and obtains Raman spectrum data showing the intensity distribution for each wavelength in the Raman scattered light. Output to the component analyzer 6. Specific examples of the photodetector 52 include a photodiode, a CCD (Charge Coupled Device), a CMOS (Complementary Metal Oxide Semiconductor), and the like.

The component analyzer 6 searches for a component (blood component) contained in blood, which is a sample SPL, based on the data given from the photodetector 52 of the spectroscope 5, and obtains the concentration of the detected blood component as the search result. It has become like. Further, the component analyzer 6 is adapted to notify the type and concentration of the blood component contained in the sample SPL as necessary.

The first embodiment and the second embodiment will be illustrated as the component analyzer 6.

(1-1) Component analyzer in the first embodiment <Structure of component analyzer>
FIG. 2 is a diagram showing an outline of the configuration of the component analyzer according to the first embodiment. As shown in FIG. 2, the component analyzer 6 is configured to include an input unit 61, a storage unit 62, a display unit 63, and a control unit 64.

The input unit 61 is a portion capable of inputting various information such as commands and set values according to the user's operation. Specific examples of the input unit 61 include a mouse, a keyboard, a connector of a portable semiconductor memory, and the like. Examples of the semiconductor memory include a USB (Universal Serial Bus) memory and a CF (Compact Flash) memory.

The storage unit 62 is a unit that stores data given from the input unit 61 or the control unit 64 and reads out the stored data. Specific examples of the storage unit 62 include a magnetic disk represented by an HD (Hard Disk), a semiconductor memory, an optical disk, or the like.

In the storage unit 62, a first storage area for storing various programs, a second storage area for storing various data such as setting data input from the input unit 61, and an expansion for developing the program and data. Areas and are included. In the first storage area of the present embodiment, a component analysis program for executing a process for analyzing a blood component is stored.

The display unit 63 is a unit that displays information shown in the data given by the control unit 64. Specific examples of the display unit 63 include a liquid crystal display, an EL (Electro Luminescence) display, a plasma display, and the like.

The control unit 64 controls the component analyzer 6 based on the program stored in the first storage area of the storage unit 62 and the data stored in the second storage area of the storage unit 62. ..

When the control unit 64 reads the component analysis program stored in the first storage area of the storage unit 62, the control unit 64 expands the read component analysis program in the expansion area of the storage unit 62. In this case, the control unit 64 functions as a spectrum acquisition unit 71, a conversion unit 72, a component identification unit 73, a quantification unit 74, and a notification unit 75, and executes a component analysis process for analyzing a component contained in blood.

The spectrum acquisition unit 71 drives the light source 2 by appropriately adjusting the intensity of the light to be emitted from the light source 2, and sequentially passes the light source 2, the reflector 3, the sample SPL, and the optical system 4 to the light detector of the spectroscope 5. The data of the Raman spectrum output from 52 is acquired.

The conversion unit 72 converts the wavelength of the Raman spectrum acquired by the spectrum acquisition unit 71 into a Raman shift amount. Specifically, each wavelength in the Raman spectrum is converted into a wave number which is the number of waves included in the unit length, and each converted wave number is the difference from the wave number of the excitation light emitted from the light source 2. Converted as a certain Raman shift amount. As a result, for example, a Raman spectrum having the vertical axis as the intensity and the horizontal axis as the wavelength becomes a Raman spectrum having the vertical axis as the intensity and the horizontal axis as the Raman shift amount. It is known that a substance has a peculiar vibration energy according to its structure, and the Raman shift amount, which is the difference between the wave number (frequency) of Raman scattered light and the wave number (frequency) of incident light, is the substance. It is a unique value that reflects the structure.

The component identification unit 73 searches for and identifies a blood component based on the Raman spectrum converted by the conversion unit 72 and the wave number set as the central wave number of the peak appearing in the Raman spectrum according to the blood component.

In the case of this embodiment, 904 cm ^-1 is set as the central wave number of the peak appearing in the Raman spectrum when the blood contains a glucose component. Further, 620 cm ^-1 and 2940 cm ^-1 are set as the central wave number of the peak appearing in the Raman spectrum when the blood contains a fructose component. Further, 546 cm ^-1 and 2898 cm ^-1 are set as the central wave number of the peak appearing in the Raman spectrum when the blood contains a maltose component. These set values are input from the input unit 61 and stored as setting data in the second storage area of the storage unit 62. Further, 470 cm ^-1 and 922 cm ^-1 are set as the central wave number of the peak appearing in the Raman spectrum when the blood contains a maltotriose component.

The component identification unit 73 recognizes each of the above central wave numbers shown in the setting data read from the second storage area, and searches for whether or not there is a peak within the range of ± 5 cm ^-1 with the central wave number as a reference. ..

Here, if even one peak is detected within the range of ± 5 cm ^{-1 based on} each of the above central wave numbers, it means that the blood component corresponding to the peak is contained in the blood. For example, when a peak is detected only within the range of 904 cm ^-1 ± 5 cm ^-1 , blood contains only glucose, which is a monosaccharide, and fructose and disaccharide, which are isomers of the glucose. It does not contain maltose or the trisaccharide maltotriose. Further, for example, if the range of 904cm ^-1 ± ^{5cm -1,} a peak in the range of 546cm ^-1 range of ± ^{5 cm -1} and 2898cm ^-1 ± ^{5cm -1} is detected, the blood is monosaccharides It contains glucose and the disaccharide maltose. Further, in the case of this example, fructose, which is an isomer of glucose, and maltotriose, which is a trisaccharide, are not included.

In this way, the component identification unit 73 can search for and identify the sugar components of monosaccharides, disaccharides, and trisaccharides contained in blood. In addition, the component identification unit 73 can search for and identify glucose, which is one of the important indicators in the discovery and treatment of diseases such as diabetes, and fructose, which is an isomer of the glucose.

The quantification unit 74 determines the concentration of the blood component corresponding to the peak based on the intensity of the peak detected by the component identification unit 73.

In the case of the present embodiment, the calibration curve data showing the relationship between the intensity of the Raman spectrum and the concentration corresponding to the intensity is stored in the second storage area of the storage unit 62. Specifically, a glucose calibration curve as illustrated in FIG. 3, a fructose calibration curve as illustrated in FIG. 4, a maltotriose calibration curve as illustrated in FIG. 5, and FIG. 6 are illustrated. The data of the calibration curve of maltotriose is stored. The vertical axis in FIGS. 3 to 6 indicates the intensity of the spectrum, and the horizontal axis indicates the concentration [mg / dl].

The quantification unit 74 reads out the data of the calibration curve of the component corresponding to the peak detected by the component identification unit 73 from the second storage area, and uses, for example, the calibration curve shown in FIGS. 3 to 6 to use the component identification unit 73. The concentration (mg / dl) of the blood component corresponding to the peak is obtained from the intensity of the peak detected by. The calibration curve data is input from the input unit 61 and stored in the second storage area of the storage unit 62.

By the way, the relationship between the intensity of the Raman spectrum and the concentration corresponding to the intensity is generally linear as shown in FIGS. 3 to 6. Using a predetermined relational expression showing this linearity relationship, the concentration of the blood component corresponding to the peak may be obtained from the intensity of the peak detected by the component identification unit 73.

The notification unit 75 notifies the type of blood component that can be detected by the component identification unit 73 and the concentration of the blood component that is detected by the component identification unit 73 and obtained by the quantification unit 74. Specifically, the type of blood component and the concentration of the blood component obtained by the quantitative unit 74 are displayed on the display screen of the display unit 63 in a predetermined display format. Instead of displaying on the display unit 63, or in addition to displaying on the display unit 63, the type of blood component and the concentration of the blood component obtained by the quantitative unit 74 are output by voice from the speaker. You may.

The control unit 64 functions as such a spectrum acquisition unit 71, a conversion unit 72, a component identification unit 73, a quantification unit 74, and a notification unit 75, and a component analysis process for analyzing a component contained in blood is executed.

<First component analysis method>
Next, the first component analysis method by the component analyzer 6 in the first embodiment will be described. FIG. 7 is a flowchart showing the first component analysis method. As shown in FIG. 7, the control unit 64 starts the component analysis at the time when the input unit 61 gives an execution command for the component analysis, and proceeds to the spectrum acquisition step SP1.

In the spectrum acquisition step SP1, the control unit 64 drives the light source 2 by appropriately adjusting the intensity of the light to be emitted from the light source 2, and shows the intensity distribution for each wavelength in the Raman scattered light generated in the sample SPL (blood). After acquiring the spectrum, the process proceeds to the wave number conversion step SP2.

In the wave number conversion step SP2, the control unit 64 converts the wavelength of the Raman spectrum acquired in the spectrum acquisition step SP1 into a Raman shift amount, and proceeds to the first search step SP3.

Control unit 64, the first search step SP3, searches whether there is a peak in the range of 620 cm ^-1 range of ± ^{5 cm -1} and 2940cm ^-1 ± ^{5cm -1.}

If no peak is detected in the first search step SP3, the control unit 64 identifies that the sample SPL (blood) does not contain fructose, and does not go through the first quantitative step SP4, but the second search step. Proceed to SP5. On the other hand, when the peak is detected in the first search step SP3, the control unit 64 identifies that the sample SPL (blood) contains fructose, and proceeds to the first quantitative step SP4.

In the first quantitative step SP4, the control unit 64 obtains the fructose concentration in the blood based on the intensity of the peak detected in the first search step SP3 and the fructose calibration curve stored in the storage unit 62. , Proceed to the second search step SP5.

Control unit 64, the second search step SP5, searches whether there is a peak in the range of 470 cm ^-1 range of ± ^{5 cm -1} and 922cm ^-1 ± ^{5cm -1.}

If no peak is detected in the second search step SP5, the control unit 64 determines that the sample SPL (blood) does not contain maltotriose, and does not go through the second quantitative step SP6 to perform the third. Proceed to search step SP7. On the other hand, when the peak is detected in the second search step SP5, the control unit 64 identifies that the sample SPL (blood) contains maltotriose, and proceeds to the second quantitative step SP6.

In the second quantitative step SP6, the control unit 64 determines the concentration of maltotriose in blood based on the intensity of the peak detected in the second search step SP5 and the calibration curve of maltotriose stored in the storage unit 62. After obtaining the above, the process proceeds to the third search step SP7.

Control unit 64, the third search step SP7, searches whether there is a peak in the range of 546cm ^-1 range of ± ^{5 cm -1} and 2898cm ^-1 ± ^{5cm -1.}

If no peak is detected in the third search step SP7, the control unit 64 identifies that the sample SPL (blood) does not contain maltose, and does not go through the third quantitative step SP8, but the fourth search step. Proceed to SP9. On the other hand, when the peak is detected in the third search step SP7, the control unit 64 identifies that the sample SPL (blood) contains maltose, and proceeds to the third quantitative step SP8.

In the third quantitative step SP8, the control unit 64 obtains the concentration of maltose in blood based on the intensity of the peak detected in the third search step SP7 and the calibration curve of maltose stored in the storage unit 62. , Proceed to the fourth search step SP9.

Control unit 64, the fourth search step SP9, searches whether there is a peak in the range of 904cm ^-1 ± ^{5cm -1.}

If no peak is detected in the fourth search step SP9, the control unit 64 determines that the sample SPL (blood) does not contain glucose, and goes to the notification step SP11 without going through the fourth quantification step SP10. move on. On the other hand, when the peak is detected in the fourth search step SP9, the control unit 64 identifies that the sample SPL (blood) contains glucose, and proceeds to the fourth quantification step SP10.

In the fourth quantification step SP10, the control unit 64 obtains the glucose concentration in the blood based on the intensity of the peak detected in the fourth search step SP9 and the glucose calibration curve stored in the storage unit 62. , Proceed to the notification step SP11.

In the notification step SP11, the control unit 64 notifies that the sugars are not contained in the blood when the concentrations of glucose, fructose, maltose and maltotriose are not obtained. On the other hand, when the control unit 64 obtains the concentration of any one of glucose, fructose, maltose and maltotriose, the control unit 64 notifies the sugar for which the concentration has been obtained and the concentration thereof. In this way, in the notification step SP11, the control unit 64 notifies the component analysis results from the first search step SP3 to the fourth quantitative step SP10, and then ends the component analysis.

In the first analysis method, blood components were searched for in the order of fructose, maltotriose, maltose, and glucose, but an order other than this order may be adopted. Further, in the above-mentioned first analysis method, when a blood component is detected, the detected blood component is quantified before searching for the next blood component, but after searching for all the various blood components, the detected blood component is quantified. The blood components detected by the search may be quantified.

<Summary>
As described above, the component analyzer 6 of the present embodiment searches for and identifies a plurality of types of sugar components contained in blood. For this reason, it is possible to subdivide and quantify blood glucose, which is one of the important indicators in the discovery and treatment of diseases such as diabetes, and more detailed information than when multiple types of sugar components are grasped in a broad sense. Can be given. In this way, the component analyzer 6 capable of improving the reliability of the analysis result is provided.

Further, in the case of the present embodiment, each of the sugar components of monosaccharides, disaccharides and trisaccharides contained in blood is searched and identified. Therefore, it is possible to subdivide the structurally similar types of saccharides and quantify them more locally, and it is possible to give detailed information accordingly.

Further, in the case of the present embodiment, 904 cm ^-1 is set as the central wave number of the peak appearing in the Raman spectrum when the blood contains a glucose component.

Experiments have confirmed that when a glucose component is contained in blood, a peak appears accurately at 904 cm ^-1 of the Raman spectrum and its reproducibility is also present. Therefore, it is possible to pinpoint the glucose component in blood and accurately quantify it.

Further, in the case of the present embodiment, 620 cm ^-1 and 2940 cm ^-1 are set as the central wave numbers of the peaks appearing in the Raman spectrum when the blood contains a fructose component.

If the fructose component is contained in the blood, that the precise peak at 620 cm ^-1 and 2940 cm ^-1 of the Raman spectrum is also its reproducibility occurrence has been confirmed by experiments. Therefore, it is possible to pinpoint the fructose component in blood and accurately quantify it.

Further, in the case of the present embodiment, 546 cm ^-1 and 2898 cm ^-1 are set as the central wave numbers of the peaks appearing in the Raman spectrum when the blood contains a maltose component.

If the maltose component is contained in the blood, that the precise peak at 546cm ^-1 and 2898cm ^-1 of Raman spectrum is also its reproducibility occurrence has been confirmed by experiments. Therefore, it is possible to pinpoint the maltose component in blood and accurately quantify it.

Further, in the case of the present embodiment, 470 cm ^-1 and 922 cm ^-1 are set as the central wave numbers of the peaks appearing in the Raman spectrum when the blood contains a maltotriose component.

If maltotriose component is contained in the blood, that the precise peak at 470 cm ^-1 and 922cm ^-1 in a Raman spectrum is also its reproducibility occurrence has been confirmed by experiments. Therefore, it is possible to pinpoint the maltotriose component in blood and accurately quantify it.

(1-2) Component Analyzer 6 in the Second Embodiment Next, the component analyzer 6 in the second embodiment will be described. The same or equivalent components as those in the first embodiment are designated by the same reference numerals, and duplicate description will be omitted as appropriate.

<Structure of component analyzer>
FIG. 8 is a diagram showing an outline of the configuration of the component analyzer according to the second embodiment. As shown in FIG. 8, in the component analysis device 6 of the present embodiment, the functional units of the control unit 64 that functions when the component analysis program stored in the first storage area of the storage unit 62 is read out are different. ..

Specifically, the control unit 64 has a component identification unit 73 for searching for a sugar component in blood in the first embodiment, whereas the control unit 64 has a component for searching for a component other than the sugar component in blood in the present embodiment. It has an identification unit 83.

In the case of this embodiment, 1002 cm ^-1 is set as the central wave number of the peak appearing in the Raman spectrum when the blood contains a urea component. Further, 820 cm ^-1 and 1682 cm ^-1 are set as the central wave number of the peak appearing in the Raman spectrum when the blood contains ascorbic acid. Further, 854 cm ^-1 and 1324 cm ^-1 are set as the central wave number of the peak appearing in the Raman spectrum when acetaminophen, which is one of the main components of the cold remedy, is contained. In addition, 804 cm ^-1 , 1032 cm ^-1 , 1152 cm ^-1 and 1198 cm ^-1 are set as the central wave number of the peak that appears in the Raman spectrum when acetylsalicylic acid, which is one of the main components of the headache drug, is contained. To.

The component identification unit 83 recognizes each of the above central wave numbers shown in the setting data read from the second storage area of the storage unit 62, and whether or not there is a peak within the range of ± 5 cm ^-1 with respect to the central wave number. Search for.

Here, if even one peak is detected within the range of ± 5 cm ^{-1 based on} each of the above central wave numbers, it means that the blood contains blood components other than sugar corresponding to the peak. means. For example, if a peak is detected only within the range of 1002 cm ^-1 ± 5 cm ^-1 , urea is contained in the blood, and depending on the concentration, renal disease or the like may be a concern. Being detectable is useful.

Further, for example, a range of 1002cm ^-1 ± ^{5cm -1,} if the peak in the range of 820 cm ^-1 ± ^{5 cm -1} and 1682 cm ^-1 ± ^{5 cm -1} is detected, the blood urea and ascorbic acid It is included. Since the concentration of ascorbic acid in blood may be one of the indicators in treatment, it is useful to be able to detect the ascorbic acid. In addition, there is a limit to the blood concentration of ascorbic acid taken in the diet or orally, and excessive intake imposes a considerable burden on the kidneys. Therefore, when the urea concentration in the blood is elevated, it can be one of the indexes to know whether the cause is due to renal disease or excessive intake of ascorbic acid, so that ascorbic acid can be detected. Will be useful.

Further, for example, a range of 1002cm ^-1 ± ^{5cm -1,} if the peak in the range of 854cm ^-1 ± ^{5cm -1} and 1324cm ^-1 ± ^{5cm -1} is detected, the blood urea and acetoamino Fen is included. As described above, acetaminophen and acetylsalicylic acid are one of the main components of the drug, and ingestion of the drug imposes a considerable burden on the kidneys. Therefore, acetaminophen and acetylsalicylic acid can be detected because when the urea concentration in the blood is elevated, it can be one of the indexes to know whether the cause is due to renal disease or drug intake. That will be useful.

In this way, the component identification unit 83 can search for components other than the sugar component contained in blood.

Further, the control unit 64 has a quantification unit 74 for quantifying sugar components in blood in the first embodiment, whereas in the present embodiment, the control unit 64 has a quantification unit 84 for quantifying components other than sugar components in blood. Have.

The quantification unit 84 obtains the concentration of the blood component corresponding to the peak based on the intensity of the peak detected by the component identification unit 83.

In the case of the present embodiment, similarly to the first embodiment, the data of the urea calibration curve, the ascorbic acid calibration curve, the acetaminophen calibration curve, and the acetylsalicylic acid calibration curve are stored in the second storage area of the storage unit 62. It is stored. This data is input from the input unit 61.

The quantification unit 84 reads out the data of the calibration curve of the component corresponding to the peak detected by the component identification unit 73 from the second storage area, and uses the calibration curve from the intensity of the peak detected by the component identification unit 83. The concentration of the blood component corresponding to the peak is obtained.

The calibration curves of urea, ascorbic acid, acetaminophen and acetylsalicylic acid have generally linearity like glucose and the like of the first embodiment. Therefore, using a predetermined linear relational expression, the concentration of the blood component corresponding to the peak may be obtained from the intensity of the peak detected by the component identification unit 83.

Further, the control unit 64 has a notification unit 75 for notifying the analysis result regarding the sugar component in blood in the first embodiment, whereas the control unit 64 notifies the analysis result regarding the component other than the component in blood in the present embodiment. It has a notification unit 85 to perform analysis.

The notification unit 85 notifies the type of blood component that can be detected by the component identification unit 83 and the concentration of the blood component that is detected by the component identification unit 83 and obtained by the quantification unit 84. Specifically, the type of blood component and the concentration of the blood component obtained by the quantification unit 84 are displayed on the display screen of the display unit 63 in a predetermined display format. Instead of displaying on the display unit 63, or in addition to displaying on the display unit 63, the type of blood component and the concentration of the blood component obtained by the quantitative unit 84 are output by voice from the speaker. You may.

In addition to this, when the concentration of any one of the drug components acetaminophen and acetylsalicylic acid is required by the quantification unit 84, the notification unit 85 sets the concentration and a predetermined value specified in advance. Compare with. Here, when the concentration determined by the quantitative unit 84 is equal to or higher than the specified value, the notification unit 85 notifies that the drug component is present in the blood.

In addition, the specified value does not need to be remeasured even if there is a drug component in the blood, considering the possibility that it affects the measurement of other components other than the drug component such as urea and glucose in the blood. It is determined based on the upper limit of the drug concentration, which is also good. This specified value is input from the input unit 61 and is stored as setting data in the second storage area of the storage unit 62. When the concentrations of both acetaminophen and acetylsalicylic acid are determined by the quantitative unit 84, the total concentration thereof may be compared with the specified value, and the higher the concentration may be compared with the specified value. ..

The component identification unit 83, the quantification unit 84, the notification unit 85, and the control unit 64 function as the spectrum acquisition unit 71 and the conversion unit 72, and a component analysis process for analyzing the components contained in blood is executed. ..

<Second component analysis method>
Next, the second component analysis method by the component analyzer 6 in the second embodiment will be described. FIG. 9 is a flowchart showing a second component analysis method. As shown in FIG. 9, the control unit 64 starts component analysis at the time when an execution command for component analysis is given from, for example, the input unit 61, and sequentially goes through the above-mentioned spectrum acquisition step SP1 and wave number conversion step SP2. , Proceed to the first search step SP30.

Control unit 64, the first search step SP30, to search whether there is a peak in the range of 1002cm ^-1 ± ^{5cm -1.}

If no peak is detected in the first search step SP30, the control unit 64 determines that the sample SPL (blood) does not contain urea, and does not go through the first quantitative step SP40, but the second search step. Proceed to SP50. On the other hand, when the peak is detected in the first search step SP30, the control unit 64 identifies that the sample SPL (blood) contains urea, and proceeds to the first quantitative step SP40.

In the first quantification step SP40, the control unit 64 obtains the urea concentration in the blood based on the intensity of the peak detected in the first search step SP30 and the urea calibration curve stored in the storage unit 62. , Proceed to the second search step SP50.

Control unit 64, the second search step SP50, to search whether there is a peak in the range of 820 cm ^-1 ± ^{5 cm -1} and 1682cm ^-1 ± ^{5cm -1.}

If no peak is detected in the second search step SP50, the control unit 64 identifies that the sample SPL (blood) does not contain ascorbic acid, and does not go through the second quantification step SP60 to perform the third search. Proceed to step SP70. On the other hand, when the peak is detected in the second search step SP50, the control unit 64 identifies that the sample SPL (blood) contains ascorbic acid, and proceeds to the second quantification step SP60.

In the second quantification step SP60, the control unit 64 obtains the concentration of ascorbic acid in the blood based on the intensity of the peak detected in the second search step SP50 and the ascorbic acid calibration curve stored in the storage unit 62. After that, the process proceeds to the third search step SP70.

Control unit 64, the third search step SP70, to search whether there is a peak in the range of 854cm ^-1 range of ± ^{5 cm -1} and 1324cm ^-1 ± ^{5cm -1.}

If no peak is detected in the third search step SP70, the control unit 64 identifies that the sample SPL (blood) does not contain acetaminophen, and does not go through the third quantitative step SP80, but the fourth Proceed to search step SP90. On the other hand, when the peak is detected in the third search step SP70, the control unit 64 identifies that the sample SPL (blood) contains acetaminophen, and proceeds to the third quantitative step SP80.

In the third quantitative step SP80, the control unit 64 determines the concentration of acetaminophen in the blood based on the intensity of the peak detected in the third search step SP70 and the calibration curve of acetaminophen stored in the storage unit 62. After obtaining the above, the process proceeds to the fourth search step SP90.

Control unit 64, the fourth search step SP90, the range of 804cm ^-1 ± ^{5cm -1,} a range of 1032cm ^-1 ± ^{5cm -1,} of 1152cm ^-1 ± ^{5cm -1} range and 1198cm ^-1 of ± ^{5 cm -1} Search for peaks within the range.

If no peak is detected in the fourth search step SP90, the control unit 64 determines that the sample SPL (blood) does not contain acetylsalicylic acid, and does not go through the fourth quantitative step SP100, but the notification step SP110. Proceed to. On the other hand, when a peak is detected in the fourth search step SP90, the control unit 64 identifies that the sample SPL (blood) contains acetylsalicylic acid, and proceeds to the fourth quantification step SP100.

In the fourth quantitative step SP100, the control unit 64 obtains the concentration of acetylsalicylic acid in blood based on the intensity of the peak detected in the fourth search step SP90 and the calibration curve of acetylsalicylic acid stored in the storage unit 62. After that, the process proceeds to the notification step SP110.

In the notification step SP110, the control unit 64 obtains the concentration of any one of the drug components, acetaminophen and acetylsalicylic acid, and if the concentration is equal to or higher than a predetermined value in the blood, Notify that there is a drug component in.

Further, when the concentration of each of urea, ascorbic acid, acetaminophen and acetylsalicylic acid is not determined, the control unit 64 notifies that these components are not contained in the blood. On the other hand, when the control unit 64 determines the concentration of any one of urea, ascorbic acid, acetaminophen and acetylsalicylic acid, the control unit 64 notifies the type of the component for which the concentration has been obtained and the concentration thereof. That is, in the notification step SP110, the control unit 64 notifies the component analysis results from the first search step SP30 to the fourth quantitative step SP100, and then ends the component analysis.

In the second analysis method, blood components were searched for in the order of urea, ascorbic acid, acetaminophen, and acetylsalicylic acid, but an order other than this order may be adopted. Further, in the above-mentioned second analysis method, when a blood component is detected, the detected blood component is quantified before searching for the next blood component, but after searching for all the various blood components, the detected blood component is quantified. The blood components detected by the search may be quantified.

<Summary>
As described above, the component analyzer 6 of the present embodiment searches for and identifies components other than the plurality of types of sugar components contained in blood. Specifically, the urea component is searched and identified. When this urea component is contained in blood, 1002 cm ^-1 is set as the central wave number of the peak appearing in the Raman spectrum.

Experiments have confirmed that when the urea component is contained in blood, it appears accurately at 1002 cm ^-1 in the Raman spectrum and has its reproducibility. Therefore, it is possible to pinpoint the urea component in blood and accurately quantify it.

Further, in the case of the present embodiment, the acetylsalicylic acid component contained in blood is also searched. ^804cm -1 as the center wavenumber of the peak the acetylsalicylic acid component appears in the Raman spectrum when contained in the ^{blood, 1032cm -1, 1152cm} -1 and 1198cm ^-1 are set.

If acetylsalicylic acid component is contained in the ^blood, 804cm -1 in a Raman ^{spectrum, 1032cm -1,} be accurately found at 1152cm ^-1 and 1198cm ^-1 are also the reproducibility has been confirmed by experiment. Therefore, it is possible to pinpoint the acetylsalicylic acid component in blood and accurately quantify it.

Further, in the case of this embodiment, the acetaminophen component contained in blood is also searched. 854cm ^-1 ± ^{5cm -1} and 1324cm ^-1 ± ^{5cm -1} is set as the center wavenumber of the peak appearing in the Raman spectrum when the acetaminophen component is contained in the blood.

If acetaminophen component is contained in the blood, it appears exactly at 854cm ^-1 ± ^{5cm -1} and 1324cm ^-1 ± ^{5cm -1} in the Raman spectrum there is also the reproducibility has been confirmed by experiment .. Therefore, it is possible to pinpoint the acetaminophen component in blood and accurately quantify it.

Further, in the case of the present embodiment, the ascorbic acid component contained in blood is also searched. 820 cm ^-1 and 1682 cm ^-1 are set as the central wave numbers of the peaks appearing in the Raman spectrum when this ascorbic acid component is contained in blood.

If ascorbic acid component is contained in the blood, it appears exactly at 820 cm ^-1 and 1682 cm ^-1 in the Raman spectrum there is also the reproducibility has been confirmed by experiments. Therefore, it is possible to pinpoint the ascorbic acid component in blood and accurately quantify it.

(2) Modified Example In the above embodiment, monosaccharides, disaccharides and trisaccharides were searched for as saccharides. However, in addition to monosaccharides, disaccharides and trisaccharides, or in place of monosaccharides, disaccharides and trisaccharides, it is possible to search for saccharides above tetrasaccharides, such as glycogen and amylose.

In the above embodiment, glucose and fructose were searched for as monosaccharides. However, it is possible to search for other monosaccharides other than glucose and fructose in addition to or in place of glucose and fructose.

Further, in the above embodiment, maltose was searched for as a disaccharide. However, in addition to or in place of maltose, it is possible to search for other monosaccharides other than the maltose, such as sucrose and lactose.

In the above embodiment, maltotriose was searched for as a trisaccharide. However, it is possible to search for other monosaccharides other than the maltotriose in addition to or in place of the maltotriose.

Further, in the above embodiment, acetylsalicylic acid and acetaminophen were searched for as drug components. However, in addition to acetylsalicylic acid and acetaminophen, or in place of acetylsalicylic acid and acetaminophen, for example, dihydrocodeine phosphate, bromvalerylurea, ephedrine hydrochloride, and other drug components other than the acetylsalicylic acid and acetaminophen. It is possible to search for. In addition, dihydrocodeine phosphate and the like may cause hallucinations due to excessive intake, and can provide an important index for the treatment of diseases and the like.

Further, in the above embodiment, searching for sugar components of monosaccharides, disaccharides and trisaccharides contained in blood and searching for components other than sugar components were separately executed. However, searching for sugar components of monosaccharides, disaccharides and trisaccharides contained in blood and searching for components other than sugar components may be executed as a series of processes. That is, each functional unit of the component identification unit, the quantification unit, and the notification unit that executes the first component analysis method and the second component analysis method may be adopted.

When the component identification unit searches for multiple types of sugar components contained in blood and also searches for and identifies urea components contained in the blood, diabetes can be prevented, detected, and treated at the same time as the diabetes. It can provide important indicators for prevention, early detection and treatment of easily complicated renal diseases. In addition, the dialysis efficiency during artificial dialysis can be controlled more closely.

In addition, if the component identification unit searches for a plurality of types of sugar components contained in blood and also searches for and identifies a drug component contained in the blood, the sugar component in the blood may be affected. It is possible to quantify the drug component to have along with blood glucose. Therefore, when blood glucose is not within the normal range, it is possible to provide an index for determining whether or not the factor is a drug component. In addition, it is possible to give an index such as the possibility of being absorbed from oral food or drink. Furthermore, it can be an indicator of whether oral administration is a factor or drug administration is a factor, such as when consciousness is impaired, so it is useful in cases of urgency. Increases.

In addition, when the component identification unit searches for a plurality of types of sugar components contained in blood and also searches for and identifies ascorbic acid components contained in the blood, information on the presence or absence of ascorbic acid deficiency due to diabetes is provided. Can be given as. Therefore, important indicators for the prevention, early detection and treatment of diabetes can be given in more detail.

Further, in the above embodiment, blood collected from a person was adopted as the sample SPL to be irradiated with the excitation light. However, the sample SPL irradiated with the excitation light may be an interstitial fluid collected from a human. It may also be the blood that flows through the human body. When the blood flowing through the human body is used as the sample SPL, for example, the control unit 64 controls the optical system to change the depth of the laser with respect to the human body, and depending on the presence or absence of blood components obtained at the depth, the inside of the human body. The focus should be on the blood vessels. Further, although human blood is used as the sample SPL, it can be applied to living organisms other than humans such as animals.

Further, in the above embodiment, the sample SPL is irradiated with excitation light having a single wavelength with respect to the sample SPL. However, as illustrated in FIG. 10, the sample SPL may be irradiated with the first laser beam and the second laser beam having different wavelengths from each other. In the component analysis system 100 of FIG. 10, for example, a first light source 21 that emits pump light which is a pulsed laser light of 1064 nm and a second light source 22 that emits Stokes light which is a pulsed laser light of 1100 nm are provided. Be done. The pump light emitted from the first light source 21 reaches the dichroic mirror DM through the light delay device 31. The optical delayer 31 changes the optical path length, for example, to match the irradiation timing of the pump light with the Stokes light. The Stokes light emitted from the second light source 22 reaches the dichroic mirror DM via the mirror M. In the dichroic mirror DM, the pump light and the Stokes light are superposed, and the superposed pump light and the Stokes light are condensed and irradiated on the sample SPL. By this irradiation, CARS (Coherent Anti-Stokes Raman Scattering) light having a wavelength different from the wavelength of the Stokes light is generated in the sample SPL. The CARS light generated in the sample SPL passes through the optical filter 42 of the optical system 4 and reaches the spectroscope 5. The optical filter 42 is a filter that cuts stray light other than CARS light. The CARS light that has reached the spectroscope 5 is divided by wavelength by the diffraction lattice 51, and Raman spectrum data showing the intensity distribution of the CARS light for each wavelength is output from the spectroscope 5. Each wavelength in this Raman spectrum is converted by the conversion unit 72 into a wave number which is the number of waves included in the unit length. However, it does not have to be converted into the Raman shift amount.

Next, the peak of the acquired Raman spectrum will be described. However, the present invention is not limited to this embodiment. In the examples, an aqueous solution sample containing a predetermined component was used instead of blood.

<Peak of glucose component>
Aqueous solution samples having different glucose concentrations were irradiated with a laser beam having a single wavelength of 785 nm, and Raman spectra of each of the aqueous solution samples were obtained. The acquisition result is shown in FIG. The system conditions for acquiring Raman spectra of aqueous solution samples having different glucose concentrations are the same. The glucose concentration of the aqueous solution sample is obtained from a spectrum obtained by isolating a sugar component using liquid chromatography manufactured by Thermo Fisher Scientific and obtaining the sugar component using a charged particle detector.
The vertical axis shown in FIG. 11 shows the intensity of the spectrum, and the horizontal axis shows the wave number [cm ^-1 ]. Further, "glco" shown in the right column of FIG. 11 means glucose, and the numerical value [mg] on the right side of the "glco" means the concentration of glucose (mg / dl) in the aqueous solution sample.
As shown in FIG. 11, when the glucose component was contained in the aqueous solution sample, it was found that the peak appeared accurately at 904 cm ^-1 of the Raman spectrum and its reproducibility was also obtained. In FIG. 11, peaks other than 904 cm ^-1 appear, but the peak is a component unrelated to the glucose component.

<Peak of fructose component>
Aqueous solutions having different fructose concentrations were irradiated with a laser beam having a single wavelength of 785 nm, and Raman spectra of each of the aqueous solutions were obtained. The acquisition results are shown in FIGS. 12 and 13. The system conditions for acquiring Raman spectra of aqueous solution samples having different fructose concentrations are the same. Moreover, the fructose concentration of the aqueous solution sample is obtained in the same manner as the above-mentioned glucose concentration.
The vertical axis shown in FIGS. 12 and 13 indicates the intensity of the spectrum, and the horizontal axis indicates the wave number [cm ^-1 ]. Further, "fructose" shown in the right column of FIGS. 12 and 13 means fructose, and the numerical value [mg] on the right side of the "fructose" means the concentration of fructose (mg / dl) in the aqueous solution sample. ..
As shown in FIGS. 12 and 13, if the fructose component is contained in the aqueous solution sample, exactly the peak at 620 cm ^-1 and 2940 cm ^-1 in the Raman spectrum was found to be also the reproducibility appearance. Although peak with other than in FIG. 13 2940 cm ^-1 peak other than in FIG. 12 620 cm ^-1 appears has appeared, the peak is irrelevant components fructose component.

<Peak of maltose component>
Aqueous solutions having different maltose concentrations were irradiated with a laser beam having a single wavelength of 785 nm, and Raman spectra of each of the aqueous samples were obtained. The acquisition results are shown in FIGS. 14 and 15. The system conditions for acquiring Raman spectra of aqueous solution samples having different maltose concentrations are the same. Moreover, the maltose concentration of the aqueous solution sample is obtained in the same manner as the above-mentioned glucose concentration.
The vertical axis shown in FIGS. 14 and 15 indicates the intensity of the spectrum, and the horizontal axis indicates the wave number [cm ^-1 ]. Further, "malto" shown in the right column of FIGS. 14 and 15 means maltose, and the numerical value [mg] on the right side of the "malto" means the concentration of maltose (mg / dl) in the aqueous solution sample. ..
As shown in FIGS. 14 and 15, if the maltose component is contained in the aqueous solution sample, exactly the peak at 546cm ^-1 and 2898cm ^-1 of Raman spectrum was found to be also the reproducibility appearance. In addition, in FIG. 14, a peak appears in other than 546 cm ^-1 , and in FIG. 15, a peak appears in other than 2898 cm ^-1 , but the peak is a component unrelated to the maltose component.

<Peak of maltotriose component>
Aqueous solutions having different malttriose concentrations were irradiated with a laser beam having a single wavelength of 785 nm, and Raman spectra of each of the aqueous solutions were obtained. The acquisition results are shown in FIGS. 16 and 17. The system conditions for acquiring Raman spectra of aqueous solution samples having different maltotriose concentrations are the same. Moreover, the maltotriose concentration of the aqueous solution sample is obtained in the same manner as the above-mentioned glucose concentration.
The vertical axis of FIGS. 16 and 17 shows the intensity of the spectrum, and the horizontal axis shows the wave number [cm ^-1 ]. Further, "maltotri" shown in the right column of FIGS. 16 and 17 means maltotriose, and the numerical value [mg] on the right side of the "maltotri" indicates the concentration of maltotriose (mg / dl) in the aqueous solution sample. Means.
As shown in FIGS. 16 and 17, if the maltotriose component is contained in the aqueous solution sample, accurately found that peaks appeared also the reproducible 470 cm ^-1 and 922cm ^-1 in a Raman spectrum It was. In addition, although a peak appears in FIG. 16 other than 470 cm ^{-1 and a} peak appears in FIG. 17 other than 922 cm ^-1 , the peak is a component unrelated to the maltotriose component.

<Peak of urea component>
Aqueous solution samples having different urea concentrations were irradiated with a laser beam having a single wavelength of 785 nm, and Raman spectra of each of the aqueous solution samples were obtained. The acquisition result is shown in FIG. The system conditions for acquiring Raman spectra of aqueous solution samples having different urea concentrations are the same. Moreover, the urea concentration of the aqueous solution sample is obtained in the same manner as the above-mentioned glucose concentration.
The vertical axis shown in FIG. 18 shows the intensity of the spectrum, and the horizontal axis shows the wave number [cm ^-1 ]. Further, "urea" shown in the right column of FIG. 18 means urea, and the numerical value [mg] on the right side of the "urea" means the concentration of urea (mg / dl) in the aqueous solution sample.
As shown in FIG. 18, when the urea component was contained in the aqueous solution sample, it was found that a peak appeared accurately at 1002 cm ^-1 of the Raman spectrum and its reproducibility was also obtained. In FIG. 18, peaks other than 1002 cm ^-1 appear, but the peak is a component unrelated to the urea component.

<Peak of acetylsalicylic acid component>
Aqueous solutions having different acetylsalicylic acid concentrations were irradiated with a laser beam having a single wavelength of 785 nm, and Raman spectra of each of the aqueous solutions were obtained. A part of this acquisition result is shown in FIGS. 19 and 20. The system conditions for acquiring Raman spectra of aqueous solution samples having different acetylsalicylic acid concentrations are the same. Moreover, the acetylsalicylic acid concentration of the aqueous solution sample is obtained in the same manner as the above-mentioned glucose concentration.
The vertical axis shown in FIGS. 19 and 20 shows the intensity of the spectrum, and the horizontal axis shows the wave number [cm ^-1 ]. Further, "aceticsalicylicicid" shown in the right column of FIGS. 19 and 20 means acetylsalicylic acid, and the numerical value [mg] on the right side of the "aceticsalicylicid" means the concentration (mg / dl) of acetylsalicylic acid in the aqueous solution sample. ing.
As shown in FIGS. 19 and 20, if the acetylsalicylic acid component is contained in the aqueous solution ^sample, 804cm -1 in a Raman ^spectrum, 1032Cm -1, precisely peaks at 1152cm ^-1 and 1198cm ^-1 are emerged It turned out that there was. In addition, although not shown here, it is known that there is reproducibility. Incidentally, FIG. 20, ^1032cm -1 with peaks other than in Figure 19 804cm ^-1 appears, a peak other than 1152cm ^-1 and 1198cm ^-1 are emerging, the peaks unrelated components and acetylsalicylic acid component Is.

<Peak of acetaminophen component>
Aqueous solutions having different acetaminophen concentrations were irradiated with a laser beam having a single wavelength of 785 nm, and Raman spectra of each of the aqueous solutions were obtained. A part of this acquisition result is shown in FIGS. 21 and 22. The system conditions for acquiring Raman spectra of aqueous solution samples having different acetaminophen concentrations are the same. Moreover, the acetaminophen concentration of the aqueous solution sample is obtained in the same manner as the above-mentioned glucose concentration.
The vertical axis shown in FIGS. 21 and 22 indicates the intensity of the spectrum, and the horizontal axis indicates the wave number [cm ^-1 ]. In addition, "ruru" shown in the right column of FIGS. 21 and 22 means acetaminophen, and the numerical value [mg] on the right side of the "ruru" indicates the concentration (mg / dl) of acetaminophen in the aqueous solution sample. Means.
As shown in FIGS. 21 and 22, if the acetaminophen component is contained in the aqueous solution sample, exactly the peak at 854cm ^-1 and 1324cm ^-1 of Raman spectrum was found to have emerged. In addition, although not shown here, it is known that there is reproducibility. In addition, although a peak appears in FIG. 21 other than 854 cm ^{-1 and a} peak appears in FIG. 22 other than 1324 cm ^-1 , the peak is a component unrelated to the acetaminophen component.

<Peak of ascorbic acid component>
Aqueous solutions having different ascorbic acid concentrations were irradiated with a laser beam having a single wavelength of 785 nm, and Raman spectra of each of the aqueous samples were obtained. A part of this acquisition result is shown in FIGS. 23 and 24. The system conditions for acquiring Raman spectra of aqueous solution samples having different ascorbic acid concentrations are the same. Moreover, the ascorbic acid concentration of the aqueous solution sample is obtained in the same manner as the above-mentioned glucose concentration.
The vertical axis shown in FIGS. 23 and 24 indicates the intensity of the spectrum, and the horizontal axis indicates the wave number [cm ^-1 ]. Further, "asco" shown in the right column of FIGS. 23 and 24 means ascorbic acid, and the numerical value [mg] on the right side of the "asco" means the concentration of ascorbic acid (mg / dl) in the aqueous solution sample. ing.
As shown in FIGS. 23 and 24, if the ascorbic acid component is contained in the aqueous solution sample, exactly the peak at 820 cm ^-1 and 1682 cm ^-1 in the Raman spectrum was found to have emerged. In addition, although not shown here, it is known that there is reproducibility. Although peaks other than in FIG. 24 1682 cm ^-1 have appeared with a peak other than in FIG. 23 820 cm ^-1 appears, the peak is irrelevant components and ascorbic acid components.

The present invention may be used in the medical industry and the like.

1 ... Component analysis system, 2 ... Light source, 3 ... Reflector, 4 ... Optical system, 5 ... Spectrometer, 6 ... Component analyzer, 61 ... Input unit, 62 ... storage unit, 63 ... display unit, 64 ... control unit, 71 ... spectrum acquisition unit, 72 ... conversion unit, 73,83 ... component identification unit, 74,84 ... -Quantitative section, 75, 85 ... Notification section.

Claims (15)

A light source that irradiates a sample, which is blood or interstitial fluid, with excitation light of a single wavelength,
A spectrum acquisition unit that acquires a Raman spectrum showing an intensity distribution for each wavelength in Raman scattered light generated in the sample, and a spectrum acquisition unit.
And the wave number is set as the center wavenumber of the peak appearing in the Raman spectrum in accordance with the component contained in the sample, on the basis of the Raman spectrum obtained by the spectrum acquisition portion, searches the component included in the sample Equipped with a component identification unit to identify
904 cm ^-1 is set as the central wave number of the peak appearing in the Raman spectrum for detecting the glucose component contained in the sample .
The component analyzer is a component analyzer characterized in that the component identification unit searches for a peak within a range of ± 5 cm ^-1 of the central wave number . The central wave number of the peak appearing in the Raman spectrum for detecting the fructose component contained in the sample is 620 cm. ^-1 And 2940 cm ^-1 Is set,
The component identification unit is ± 5 cm of the central wave number. ^-1 Further search for peaks within the range of
The component analyzer according to claim 1. The central wave number of the peak appearing in the Raman spectrum for detecting the maltose component contained in the sample is 546 cm. ^-1 And 2898 cm ^-1 Is set,
The component identification unit is ± 5 cm of the central wave number. ^-1 Further search for peaks within the range of
The component analyzer according to claim 1 or 2. The central wave number of the peak appearing in the Raman spectrum for detecting the maltotriose component contained in the sample is 470 cm. ^-1 And 922 cm ^-1 Is set,
The component identification unit is ± 5 cm of the central wave number. ^-1 Further search for peaks within the range of
The component analyzer according to any one of claims 1 to 3, wherein the component analyzer is characterized by the above. The central wave number of the peak appearing in the Raman spectrum for detecting the urea component contained in the sample is 1002 cm. ^-1 Is set,
The component identification unit is ± 5 cm of the central wave number. ^-1 Further search for peaks within the range of
The component analyzer according to any one of claims 1 to 4, wherein the component analyzer is characterized by the above. The central wave number of the peak appearing in the Raman spectrum for detecting the acetylsalicylic acid component contained in the sample is 804 cm. ^-1 1032 cm ^-1 1,152 cm ^-1 And 1198 cm ^-1 Is set,
The component identification unit is ± 5 cm of the central wave number. ^-1 Further search for peaks within the range of
The component analyzer according to any one of claims 1 to 5, characterized in that. The central wave number of the peak appearing in the Raman spectrum for detecting the acetaminophen component contained in the sample is 854 cm. ^-1 And 1324 cm ^-1 Is set,
The component identification unit is ± 5 cm of the central wave number. ^-1 Further search for peaks within the range of
The component analyzer according to any one of claims 1 to 6, characterized in that. The central wave number of the peak appearing in the Raman spectrum for detecting the ascorbic acid component contained in the sample is 820 cm. ^-1 And 1682 cm ^-1 Is set,
The component identification unit is ± 5 cm of the central wave number. ^-1 Further search for peaks within the range of
The component analyzer according to any one of claims 1 to 7, wherein the component analyzer is characterized by the above. A light source that irradiates a sample, which is blood or interstitial fluid, with excitation light of a single wavelength,
A spectrum acquisition unit that acquires a Raman spectrum showing an intensity distribution for each wavelength in Raman scattered light generated in the sample, and a spectrum acquisition unit.
And the wave number is set as the center wavenumber of the peak appearing in the Raman spectrum in accordance with the component contained in the sample, on the basis of the Raman spectrum obtained by the spectrum acquisition portion, searches the component included in the sample Equipped with a component identification unit to identify
620 cm ^-1 and 2940 cm ^-1 are set as the central wave numbers of the peaks appearing in the Raman spectrum for detecting the fructose component contained in the sample .
The component analyzer is a component analyzer characterized in that the component identification unit searches for a peak within a range of ± 5 cm ^-1 of the central wave number . The central wave number of the peak appearing in the Raman spectrum for detecting the maltose component contained in the sample is 546 cm. ^-1 And 2898 cm ^-1 Is set,
The component identification unit is ± 5 cm of the central wave number. ^-1 Further search for peaks within the range of
The component analyzer according to claim 9. The central wave number of the peak appearing in the Raman spectrum for detecting the maltotriose component contained in the sample is 470 cm. ^-1 And 922 cm ^-1 Is set,
The component identification unit is ± 5 cm of the central wave number. ^-1 Further search for peaks within the range of
The component analyzer according to claim 9 or 10. A light source that irradiates a sample, which is blood or interstitial fluid, with excitation light of a single wavelength,
A spectrum acquisition unit that acquires a Raman spectrum showing an intensity distribution for each wavelength in Raman scattered light generated in the sample, and a spectrum acquisition unit.
And the wave number is set as the center wavenumber of the peak appearing in the Raman spectrum in accordance with the component contained in the sample, on the basis of the Raman spectrum obtained by the spectrum acquisition portion, searches the component included in the sample Equipped with a component identification unit to identify
470 cm ^-1 and 922 cm ^-1 are set as the central wave numbers of the peaks appearing in the Raman spectrum for detecting the maltotriose component contained in the sample .
The component analyzer is a component analyzer characterized in that the component identification unit searches for a peak within a range of ± 5 cm ^-1 of the central wave number . The central wave number of the peak appearing in the Raman spectrum for detecting the maltose component contained in the sample is 546 cm. ^-1 And 2898 cm ^-1 Is set,
The component identification unit is ± 5 cm of the central wave number. ^-1 Further search for peaks within the range of
The component analyzer according to claim 12. A spectrum acquisition step of irradiating a sample of blood or interstitial fluid with excitation light of a single wavelength and acquiring a Raman spectrum showing an intensity distribution for each wavelength in Raman scattered light generated in the sample.
A wave number conversion step for converting the wavelength of the Raman spectrum into a Raman shift amount indicated by a wave number, and
620 cm in the Raman spectrum ^-1 ± 5 cm ^-1 Range and 2940 cm ^-1 ± 5 cm ^-1 The first search step to search for peaks in the range of
470 cm in the Raman spectrum ^-1 ± 5 cm ^-1 Range and 922 cm ^-1 ± 5 cm ^-1 The second search step to search for peaks in the range of
546 cm in the Raman spectrum ^-1 ± 5 cm ^-1 Range and 2898 cm ^-1 ± 5 cm ^-1 The third search step to search for peaks in the range of
904 cm in the Raman spectrum ^-1 ± 5 cm ^-1 The fourth search step to search for peaks in the range of
With
In the first search step, 620 cm ^-1 ± 5 cm ^-1 Range and 2940 cm ^-1 ± 5 cm ^-1 If a peak is detected in the range of, it is identified that the sample contains fructose.
470 cm in the second search step ^-1 ± 5 cm ^-1 Range and 922 cm ^-1 ± 5 cm ^-1 If a peak is detected in the range of, it is identified that the sample contains maltotriose.
546 cm in the third search step ^-1 ± 5 cm ^-1 Range and 2898 cm ^-1 ± 5 cm ^-1 If a peak is detected in the range of, it is identified that the sample contains maltose.
904 cm in the fourth search step ^-1 ± 5 cm ^-1 If a peak is detected in the range of, the sample is identified as containing glucose.
A component analysis method characterized by that. A spectrum acquisition step of irradiating a sample of blood or interstitial fluid with excitation light of a single wavelength and acquiring a Raman spectrum showing an intensity distribution for each wavelength in Raman scattered light generated in the sample.
A wave number conversion step for converting the wavelength of the Raman spectrum into a Raman shift amount indicated by a wave number, and
1002 cm in the Raman spectrum ^-1 ± 5 cm ^-1 The first search step to search for peaks in the range of
820 cm in the Raman spectrum ^-1 ± 5 cm ^-1 Range and 1682 cm ^-1 ± 5 cm ^-1 The second search step to search for peaks in the range of
854 cm in the Raman spectrum ^-1 ± 5 cm ^-1 Range and 1324 cm ^-1 ± 5 cm ^-1 The third search step to search for peaks in the range of
804 cm in the Raman spectrum ^-1 ± 5 cm ^-1 Range, 1032 cm ^-1 ± 5 cm ^-1 Range, 1152 cm ^-1 ± 5 cm ^-1 Range and 1198 cm ^-1 ± 5 cm ^-1 The fourth search step to search for peaks in the range of
With
1002 cm in the first search step ^-1 ± 5 cm ^-1 When a peak is detected in the range of, it is identified that the sample contains urea, and the sample is identified as containing urea.
In the second search step, 820 cm ^-1 ± 5 cm ^-1 Range and 1682 cm ^-1 ± 5 cm ^-1 When a peak is detected in the range of, it is identified that the sample contains ascorbic acid, and the sample is identified as containing ascorbic acid.
In the third search step, 854 cm ^-1 ± 5 cm ^-1 Range and 1324 cm ^-1 ± 5 cm ^-1 If a peak is detected in the range of, it is identified that the sample contains acetaminophen.
804 cm in the fourth search step ^-1 ± 5 cm ^-1 Range, 1032 cm ^-1 ± 5 cm ^-1 Range, 1152 cm ^-1 ± 5 cm ^-1 Range and 1198 cm ^-1 ± 5 cm ^-1 If a peak is detected in the range of, it is identified that the sample contains acetylsalicylic acid.
A component analysis method characterized by that.

Images